Abstract
Objective: The purpose of this study was to determine whether amniotic fluid levels of annexin A5 (AF-AnxA5) may be associated with intrauterine growth restriction (IUGR). Study design: Amniotic fluid was obtained in a cohort of pregnant patients (n = 172) undergoing amniocentesis at 15 to 24 weeks' gestation and annexin A5 (AnxA5) levels were determined with enzyme-linked immunosorbent assay (ELISA). Patients who developed IUGR were compared with the remainder of the cohort. Results: AF-AnxA5 levels significantly increased through gestation (P = .003). The mean level of AF-AnxA5 in IUGR patients (n = 15) was significantly higher (P = .028) than in the remainder of the cohort (n = 130). Elevated AF-AnxA5 > 20 ng/mL was associated with a relative risk of 3.5 for the development of IUGR (P = .023). Conclusion: AnxA5 is present in amniotic fluid and increases through gestation from 15 to 24 weeks. Elevated AF-AnxA5 levels were present in patients who developed IUGR. AF-AnxA5 may be a useful marker for identifying pregnancy abnormalities.
Original language | English |
---|---|
Pages (from-to) | 1371-1376 |
Number of pages | 6 |
Journal | American Journal of Obstetrics and Gynecology |
Volume | 194 |
Issue number | 5 |
DOIs | |
State | Published - May 2006 |
Externally published | Yes |
Keywords
- Amniotic fluid
- Amniotic fluid (AF)
- Annexin A5 (AnxA5)
- Antiphospholipid syndrome (APS)
- Intrauterine growth restriction (IUGR)
- Placenta
- Placental vascular complications
- Pregnancy complications